{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T10:35:29Z","timestamp":1774866929243,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,2,4]],"date-time":"2019-02-04T00:00:00Z","timestamp":1549238400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute of Health Research","doi-asserted-by":"crossref","award":["PB-PG-0711-25112"],"award-info":[{"award-number":["PB-PG-0711-25112"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12882-019-1216-2","type":"journal-article","created":{"date-parts":[[2019,2,4]],"date-time":"2019-02-04T12:03:23Z","timestamp":1549281803000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["A randomized controlled trial of different serum phosphate ranges in subjects on hemodialysis"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7834-5453","authenticated-orcid":false,"given":"Ramya","family":"Bhargava","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip A.","family":"Kalra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Hann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Brenchley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Hurst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alastair J.","family":"Hutchison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,2,4]]},"reference":[{"key":"1216_CR1","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1681\/ASN.V12102131","volume":"12","author":"SK Ganesh","year":"2001","unstructured":"Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol. 2001;12:2131\u20138.","journal-title":"J Am Soc Nephrol"},{"key":"1216_CR2","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1053\/ajkd.1998.v31.pm9531176","volume":"31","author":"GA Block","year":"1998","unstructured":"Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998;31:607\u201317.","journal-title":"Am J Kidney Dis"},{"key":"1216_CR3","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","volume":"15","author":"GA Block","year":"2004","unstructured":"Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15:2208\u201318.","journal-title":"J Am Soc Nephrol"},{"key":"1216_CR4","first-page":"870","volume":"32","author":"A Lenglet","year":"2016","unstructured":"Lenglet A, Liabeuf S, El EN, Brisset S, Mansour J, Lemaire-Hurtel AS, et al. Efficacy and safety of nicotinamide in haemodialysis patients: the NICOREN study. Nephrol Dial Transplant. 2016;32:870.","journal-title":"Nephrol Dial Transplant"},{"key":"1216_CR5","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/ki.2014.58","volume":"86","author":"J Floege","year":"2014","unstructured":"Floege J, Covic AC, Ketteler M, Rastogi A, Chong EM, Gaillard S, et al. A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients. Kidney Int. 2014;86:638\u201347.","journal-title":"Kidney Int"},{"key":"1216_CR6","doi-asserted-by":"publisher","first-page":"3707","DOI":"10.1093\/ndt\/gfq292","volume":"25","author":"AL Francisco de","year":"2010","unstructured":"de Francisco AL, Leidig M, Covic AC, Ketteler M, Benedyk-Lorens E, Mircescu GM, et al. Evaluation of calcium acetate\/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability. Nephrol Dial Transplant. 2010;25:3707\u201317.","journal-title":"Nephrol Dial Transplant"},{"key":"1216_CR7","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1471-2369-14-40","volume":"14","author":"AJ Hutchison","year":"2013","unstructured":"Hutchison AJ, Gill M, Copley JB, Poole L, Wilson RJ. Lanthanum carbonate versus placebo for management of hyperphosphatemia in patients undergoing peritoneal dialysis: a subgroup analysis of a phase 2 randomized controlled study of dialysis patients. BMC Nephrol. 2013;14:40.","journal-title":"BMC Nephrol"},{"key":"1216_CR8","doi-asserted-by":"publisher","first-page":"3677","DOI":"10.1093\/ndt\/gfn310","volume":"23","author":"AJ Hutchison","year":"2008","unstructured":"Hutchison AJ, Laville M. Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden. Nephrol Dial Transplant. 2008;23:3677\u201384.","journal-title":"Nephrol Dial Transplant"},{"key":"1216_CR9","doi-asserted-by":"publisher","first-page":"c61","DOI":"10.1159\/000088932","volume":"102","author":"AJ Hutchison","year":"2006","unstructured":"Hutchison AJ, Maes B, Vanwalleghem J, Asmus G, Mohamed E, Schmieder R, et al. Long-term efficacy and tolerability of lanthanum carbonate: results from a 3-year study. Nephron Clin Pract. 2006;102:c61\u201371.","journal-title":"Nephron Clin Pract"},{"key":"1216_CR10","doi-asserted-by":"publisher","first-page":"c8","DOI":"10.1159\/000084653","volume":"100","author":"AJ Hutchison","year":"2005","unstructured":"Hutchison AJ, Maes B, Vanwalleghem J, Asmus G, Mohamed E, Schmieder R, et al. Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate. Nephron Clin Pract. 2005;100:c8\u201319.","journal-title":"Nephron Clin Pract"},{"key":"1216_CR11","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1093\/ndt\/gfh282","volume":"19","author":"AJ Hutchison","year":"2004","unstructured":"Hutchison AJ, Speake M, Al-Baaj F. Reducing high phosphate levels in patients with chronic renal failure undergoing dialysis: a 4-week, dose-finding, open-label study with lanthanum carbonate. Nephrol Dial Transplant. 2004;19:1902\u20136.","journal-title":"Nephrol Dial Transplant"},{"key":"1216_CR12","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/ki.2014.177","volume":"86","author":"AJ Hutchison","year":"2014","unstructured":"Hutchison AJ. Novel phosphate binders: plus ca change, plus c'est la meme chose. Kidney Int. 2014;86:471\u20134.","journal-title":"Kidney Int"},{"key":"1216_CR13","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/nrneph.2011.112","volume":"7","author":"AJ Hutchison","year":"2011","unstructured":"Hutchison AJ, Smith CP, Brenchley PE. Pharmacology, efficacy and safety of oral phosphate binders. Nat Rev Nephrol. 2011;7:578\u201389.","journal-title":"Nat Rev Nephrol"},{"key":"1216_CR14","first-page":"507","volume":"21","author":"H Park","year":"2015","unstructured":"Park H, Rascati KL, Keith MS. Managing oral phosphate binder medication expenditures within the Medicare bundled end-stage renal disease prospective payment system: economic implications for large U.S. dialysis organizations. J Manag Care Spec Pharm. 2015;21:507\u201314.","journal-title":"J Manag Care Spec Pharm"},{"key":"1216_CR15","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1007\/s12325-014-0170-4","volume":"31","author":"K Ramakrishnan","year":"2014","unstructured":"Ramakrishnan K, Braunhofer P, Newsome B, Lubeck D, Wang S, Deuson J, et al. The economic impact of improving phosphate binder therapy adherence and attainment of guideline phosphorus goals in hemodialysis patients: a Medicare cost-offset model. Adv Ther. 2014;31:1272\u201386.","journal-title":"Adv Ther"},{"key":"1216_CR16","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.clinthera.2014.06.036","volume":"36","author":"MS Keith","year":"2014","unstructured":"Keith MS, Wilson RJ, Preston P, Copley JB. Cost-minimization analysis of lanthanum carbonate versus sevelamer hydrochloride in US patients with end-stage renal disease. Clin Ther. 2014;36:1276\u201386.","journal-title":"Clin Ther"},{"key":"1216_CR17","doi-asserted-by":"publisher","first-page":"161","DOI":"10.2147\/IJNRD.S41626","volume":"7","author":"S Ossareh","year":"2014","unstructured":"Ossareh S. Clinical and economic aspects of sevelamer therapy in end-stage renal disease patients. Int J Nephrol Renov Dis. 2014;7:161\u20138.","journal-title":"Int J Nephrol Renov Dis"},{"key":"1216_CR18","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/hdi.12315","volume":"20","author":"RB Fissell","year":"2016","unstructured":"Fissell RB, Karaboyas A, Bieber BA, Sen A, Li Y, Lopes AA, et al. Phosphate binder pill burden, patient-reported non-adherence, and mineral bone disorder markers: findings from the DOPPS. Hemodial Int. 2016;20:38\u201349.","journal-title":"Hemodial Int"},{"key":"1216_CR19","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1053\/j.jrn.2013.11.004","volume":"24","author":"S Wang","year":"2014","unstructured":"Wang S, Anum EA, Ramakrishnan K, Alfieri T, Braunhofer P, Newsome B. Reasons for phosphate binder discontinuation vary by binder type. J Ren Nutr. 2014;24:105\u20139.","journal-title":"J Ren Nutr"},{"key":"1216_CR20","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1310\/hpj5104-312","volume":"51","author":"R Robison","year":"2016","unstructured":"Robison R, Cooney D, Low MB, Desai N. Sevelamer carbonate and lanthanum usage evaluation and cost considerations at a veteran\u2019s affairs medical center. Hosp Pharm. 2016;51:312\u20139.","journal-title":"Hosp Pharm"},{"key":"1216_CR21","doi-asserted-by":"publisher","first-page":"579434","DOI":"10.1155\/2015\/579434","volume":"2015","author":"R Bhargava","year":"2015","unstructured":"Bhargava R, Kalra PA, Brenchley P, Hurst H, Hutchison A. A study to inform the design of a national multicentre randomised controlled trial to evaluate if reducing serum phosphate to normal levels improves clinical outcomes including mortality, cardiovascular events, bone pain, or fracture in patients on dialysis. Int J Nephrol. 2015;2015:579434.","journal-title":"Int J Nephrol"},{"key":"1216_CR22","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/S0140-6736(13)60897-1","volume":"382","author":"SA Jamal","year":"2013","unstructured":"Jamal SA, Vandermeer B, Raggi P, Mendelssohn DC, Chatterley T, Dorgan M, et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet. 2013;382:1268\u201377.","journal-title":"Lancet"},{"key":"1216_CR23","doi-asserted-by":"publisher","first-page":"965","DOI":"10.2215\/CJN.10941016","volume":"12","author":"R Wald","year":"2017","unstructured":"Wald R, Rabbat CG, Girard L, Garg AX, Tennankore K, Tyrwhitt J, et al. Two phosphAte taRGets in end-stage renal disease trial (TARGET): a randomized controlled trial. Clin J Am Soc Nephrol. 2017;12:965\u201373.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1216_CR24","doi-asserted-by":"publisher","first-page":"697","DOI":"10.2215\/CJN.00560206","volume":"1","author":"SM Moe","year":"2006","unstructured":"Moe SM, Chertow GM. The case against calcium-based phosphate binders. Clin J Am Soc Nephrol. 2006;1:697\u2013703.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1216_CR25","doi-asserted-by":"publisher","first-page":"539","DOI":"10.2215\/CJN.06370615","volume":"11","author":"PS Parfrey","year":"2016","unstructured":"Parfrey PS, Block GA, Correa-Rotter R, Drueke TB, Floege J, Herzog CA, et al. Lessons learned from EVOLVE for planning of future randomized trials in patients on dialysis. Clin J Am Soc Nephrol. 2016;11:539\u201346.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1216_CR26","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1056\/NEJMoa021583","volume":"347","author":"G Eknoyan","year":"2002","unstructured":"Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med. 2002;347:2010\u20139.","journal-title":"N Engl J Med"},{"key":"1216_CR27","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","volume":"367","author":"GM Chertow","year":"2012","unstructured":"Chertow GM, Block GA, Correa-Rotter R, Drueke TB, Floege J, Goodman WG, et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2012;367:2482\u201394.","journal-title":"N Engl J Med"},{"key":"1216_CR28","first-page":"330","volume":"24","author":"HH Shah","year":"2015","unstructured":"Shah HH, Hazzan AD, Fishbane S. Novel iron-based phosphate binders in patients with chronic kidney disease. Curr Opin Nephrol Hypertens. 2015;24:330\u20135.","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"Suppl 1","key":"1216_CR29","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1159\/000444819","volume":"132","author":"R Steenkamp","year":"2016","unstructured":"Steenkamp R, Rao A, Fraser S. UK renal registry 18th annual report (December 2015) chapter 5: survival and causes of death in UK adult patients on renal replacement therapy in 2014: national and Centre-specific analyses. Nephron. 2016;132(Suppl 1):111\u201344.","journal-title":"Nephron"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-019-1216-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12882-019-1216-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-019-1216-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,11]],"date-time":"2022-09-11T10:32:32Z","timestamp":1662892352000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-019-1216-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,4]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1216"],"URL":"https:\/\/doi.org\/10.1186\/s12882-019-1216-2","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,4]]},"assertion":[{"value":"10 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All trial procedures adhered to the Declaration of Helsinki and the trial protocol was reviewed and approved by the National Regional Ethics Committee East Midlands Derby, REC Ref No. 13\/EM\/0042. Written informed consent was obtained from all participants.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Fifty percent of the study clinician\u2019s salary was funded by an unrestricted educational grant from Shire pharmaceuticals. Prof Alastair J Hutchison and Prof Philip Kalra have been on the advisory committees for Shire pharmaceuticals and Amgen and heave been recipients of unrestricted research grants from these parties on different occasions. None of these companies had any input into the design or conduct of the trial. The results presented in this paper have not been published previously in whole or part, except in abstract format.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"37"}}